Trials / Completed
CompletedNCT01263236
A Study of LY2940094 in Major Depressive Disorder
A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study of LY2940094 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- BlackThorn Therapeutics, Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of LY2940094 in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2940094 | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-12-20
- Last updated
- 2017-02-03
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT01263236. Inclusion in this directory is not an endorsement.